US2004058973A1PendingUtilityA1

Compositions for treating apnea and related disorders containing optically pure R(+) ondansetron

54
Assignee: SEPRACOR INCPriority: Mar 1, 1999Filed: Sep 22, 2003Published: Mar 25, 2004
Est. expiryMar 1, 2019(expired)· nominal 20-yr term from priority
Inventors:Paul RubinTimothy J. Barberich
A61P 43/00A61K 31/415A61P 11/00A61K 31/4178
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods for the treatment, management, or prevention of apnea and apnea disorders, or symptoms thereof, using a therapeutically effective amount of substantially optically pure R(+) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(−) stereoisomer

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of treating apnea or an apnea disorder in a patient which comprises administering to said patient a therapeutically effective amount of R(+) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(−) stereoisomer.  
     
     
         2 . A method of preventing or managing apnea or an apnea disorder in a patient which comprises administering to said patient a therapeutically effective amount of R(+) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(−) stereoisomer.  
     
     
         3 . The method according to  claim 1 , wherein the apnea or apnea disorder being treated is selected from the group consisting of central apnea, deglutition apnea, obstructive apnea, sleep apnea, and sleep induced apnea.  
     
     
         4 . The method according to  claim 1 , wherein the patient is a human.  
     
     
         5 . The method of  claim 1 , wherein R(+) ondansetron is administered orally.  
     
     
         6 . The method of  claim 5 , wherein R(+) ondansetron is administered as a tablet or a capsule.  
     
     
         7 . The method according to  claim 5 , wherein said R(+) ondansetron is administered from one to four times a day.  
     
     
         8 . The method according to  claim 5 , wherein the therapeutically effective amount administered is from about 0.001 mg to about 35 mg.  
     
     
         9 . The method according to  claim 8 , wherein the amount administered is from about 0.5 mg to about 30 mg.  
     
     
         10 . The method according to  claim 9 , wherein the amount administered is from about 1 mg to about 25 mg.  
     
     
         11 . The method of  claim 1 , wherein R(+) ondansetron is administered parenterally.  
     
     
         12 . The method according to  claim 1 , wherein the amount of R(+) ondansetron, or a pharmaceutically acceptable salt thereof provided, is greater than approximately 90% by weight of the total ondansetron.  
     
     
         13 . The method according to  claim 1 , wherein R(+) ondansetron or a pharmaceutically acceptable salt thereof, substantially free of its S(−) stereoisomer, is administered together with a pharmaceutically acceptable carrier.  
     
     
         14 . The method according to  claim 1 , wherein R(+) ondansetron hydrochloride is administered.  
     
     
         15 . A method of treating apnea or an apnea disorder in a patient which comprises administering an amount of R(+) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(−) stereoisomer, and a therapeutically effective amount of at least one anti-apnea therapeutic agent.  
     
     
         16 . A method of preventing or managing apnea or an apnea disorder in a patient which comprises administering an amount of R(+) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(−) stereoisomer, and a therapeutically effective amount of at least one anti-apnea therapeutic agent.  
     
     
         17 . The method according to  claim 15 , wherein the apnea or apnea disorder being treated is selected from the group consisting of central apnea, deglutition apnea, obstructive apnea, sleep apnea, and sleep induced apnea.  
     
     
         18 . The method of  claim 15 , which comprises administering R(+) ondansetron and the at least one therapeutic agent concurrently or sequentially.  
     
     
         19 . The method of claims  15 , wherein said R(+) ondansetron is administered orally from one to four times per day.  
     
     
         20 . The method according to  claim 15 , wherein the amount administered is from about 0.001 mg to about 35 mg.

Join the waitlist — get patent alerts

Track US2004058973A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.